Related Experiment Video

Updated: Jun 4, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents

Christina Menke1, Lianghua Bin, Jacqueline Thorburn

  • 1Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA.

Cancer Research
|March 3, 2011
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance is a challenge in cancer therapy. While many drugs synergize with TRAIL in sensitive cells, only proteasome inhibitors effectively overcome TRAIL resistance, suggesting a new approach for combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonists show promise as anticancer agents.
  • Acquired resistance to TRAIL is a significant impediment to its clinical application.
  • Combination therapies combining TRAIL agonists with cytotoxic drugs have yielded disappointing results in clinical trials.

Purpose of the Study:

  • To investigate whether drugs that synergize with TRAIL in sensitive cells can overcome TRAIL resistance.
  • To identify therapeutic strategies that can overcome TRAIL resistance in cancer treatment.
  • To evaluate the relationship between drug synergy and resistance-overcoming capacity in TRAIL combination therapy.

Main Methods:

  • Creation of isogenic tumor cell lines with acquired or defined mechanisms of TRAIL resistance.
  • Comparison of TRAIL-sensitive parental cell lines with resistant counterparts.
  • Assessment of synergy and resistance-overcoming potential of various anticancer drugs in combination with TRAIL.

Main Results:

  • Diverse classes of anticancer drugs synergized with TRAIL in sensitive cells.
  • Most agents failed to overcome acquired TRAIL resistance, with no correlation between synergy and resistance-overcoming ability.
  • Proteasome inhibitors were an exception, demonstrating the ability to overcome various TRAIL resistance mechanisms.

Conclusions:

  • Drug selection for TRAIL receptor agonist combination therapy should prioritize agents that overcome resistance, not solely those that synergize.
  • Proteasome inhibitors represent a promising class of drugs for overcoming TRAIL resistance in combination therapies.
  • Rethinking combination strategies is crucial for improving the efficacy of TRAIL-targeted cancer treatments.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...